PL2547205T3 - Nowe sposoby do celowania nowotworowych komórek macierzystych - Google Patents

Nowe sposoby do celowania nowotworowych komórek macierzystych

Info

Publication number
PL2547205T3
PL2547205T3 PL11757135.6T PL11757135T PL2547205T3 PL 2547205 T3 PL2547205 T3 PL 2547205T3 PL 11757135 T PL11757135 T PL 11757135T PL 2547205 T3 PL2547205 T3 PL 2547205T3
Authority
PL
Poland
Prior art keywords
stem cells
cancer stem
novel methods
targeting cancer
targeting
Prior art date
Application number
PL11757135.6T
Other languages
English (en)
Polish (pl)
Inventor
Chiang Jia Li
David Leggett
Youzhi Li
Wei Li
Original Assignee
1Globe Biomedical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co., Ltd. filed Critical 1Globe Biomedical Co., Ltd.
Publication of PL2547205T3 publication Critical patent/PL2547205T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11757135.6T 2010-03-19 2011-03-21 Nowe sposoby do celowania nowotworowych komórek macierzystych PL2547205T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31589010P 2010-03-19 2010-03-19
US31588610P 2010-03-19 2010-03-19
US32581410P 2010-04-19 2010-04-19
PCT/US2011/029283 WO2011116399A1 (en) 2010-03-19 2011-03-21 Novel methods for targeting cancer stem cells

Publications (1)

Publication Number Publication Date
PL2547205T3 true PL2547205T3 (pl) 2024-07-08

Family

ID=47678420

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11757135.6T PL2547205T3 (pl) 2010-03-19 2011-03-21 Nowe sposoby do celowania nowotworowych komórek macierzystych

Country Status (18)

Country Link
US (2) US9730909B2 (cg-RX-API-DMAC7.html)
EP (1) EP2547205B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013522326A (cg-RX-API-DMAC7.html)
CN (1) CN103025159A (cg-RX-API-DMAC7.html)
AU (1) AU2011227023B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012023660B8 (cg-RX-API-DMAC7.html)
CA (2) CA2946890A1 (cg-RX-API-DMAC7.html)
DK (1) DK2547205T3 (cg-RX-API-DMAC7.html)
ES (1) ES2987670T3 (cg-RX-API-DMAC7.html)
FI (1) FI2547205T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240658T1 (cg-RX-API-DMAC7.html)
LT (1) LT2547205T (cg-RX-API-DMAC7.html)
PL (1) PL2547205T3 (cg-RX-API-DMAC7.html)
RS (1) RS65536B1 (cg-RX-API-DMAC7.html)
RU (1) RU2591823C2 (cg-RX-API-DMAC7.html)
SI (1) SI2547205T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400193T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011116399A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
RU2657750C1 (ru) * 2010-03-19 2018-06-15 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
US10017488B2 (en) 2014-02-07 2018-07-10 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof
AU2015272560B2 (en) 2014-06-09 2019-02-14 Kyoto Pharmaceutical Industries, Ltd. Novel anticancer agent
CN107666906A (zh) 2015-04-17 2018-02-06 波士顿生物医药有限公司 用于治疗癌症的方法
CN107708700A (zh) 2015-04-17 2018-02-16 波士顿生物医药有限公司 用于治疗癌症的方法
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US10953369B2 (en) * 2018-03-08 2021-03-23 Georgia Tech Research Corporation Spirocentric compounds and polymers thereof
EP3865130A4 (en) 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-REFRACTORY CANCER
CN111825644B (zh) * 2019-04-18 2023-07-28 中国医学科学院药物研究所 2,3-二氢萘并[2,3-b]呋喃-4,9-二酮类化合物及其制备方法和用途
CN117350965A (zh) * 2023-10-07 2024-01-05 中国原子能科学研究院 对象内放射性微球的指标预估装置

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
WO2000044774A2 (en) 1999-01-27 2000-08-03 The University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
MXPA02000828A (es) 1999-08-02 2002-07-30 Hoffmann La Roche Nuevos antagonistas retinoiides selectivos.
JP2001097860A (ja) * 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) * 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
WO2003045357A1 (en) 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび/またはアポプトーシス細胞による一定の被験体を前処理するための方法
ATE337014T1 (de) 2002-03-15 2006-09-15 Natimmune As Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
EP1551392A4 (en) * 2002-09-17 2006-09-20 Arqule Inc NEW LAPACHO COMPOUNDS AND APPLICATION METHOD THEREFOR
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
US7745468B2 (en) 2003-12-11 2010-06-29 Board of Regents, University of Texas Systems The Compounds for treatment of cell proliferative diseases
WO2005110477A2 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
RU2007123675A (ru) 2004-11-24 2008-12-27 Новартис АГ (CH) Комбинации ингибиторов jak
EP1853242A4 (en) 2005-02-25 2009-11-18 Univ Michigan LOW MOLECULAR STAT3 INHIBITORS AND THEIR USES
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
CN101142202A (zh) * 2005-03-16 2008-03-12 太日保日本株式会社 抗癌化合物及其中间体和生产方法
US20060252073A1 (en) 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2007100640A2 (en) 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2007115269A2 (en) 2006-03-31 2007-10-11 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性2−(1−ヒドロキシエチル)−5−ヒドロキシナフト[2,3−b]フラン−4,9−ジオンの製法
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
RU2657750C1 (ru) * 2010-03-19 2018-06-15 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки

Also Published As

Publication number Publication date
RU2012144420A (ru) 2014-04-27
BR112012023660B8 (pt) 2021-05-25
CN103025159A (zh) 2013-04-03
AU2011227023A1 (en) 2012-09-27
SI2547205T1 (sl) 2024-08-30
WO2011116399A1 (en) 2011-09-22
RS65536B1 (sr) 2024-06-28
CA2793527A1 (en) 2011-09-22
EP2547205A4 (en) 2013-08-14
DK2547205T3 (da) 2024-05-27
US20130028944A1 (en) 2013-01-31
EP2547205A1 (en) 2013-01-23
RU2591823C2 (ru) 2016-07-20
JP2013522326A (ja) 2013-06-13
US9730909B2 (en) 2017-08-15
CA2946890A1 (en) 2011-09-22
SMT202400193T1 (it) 2024-07-09
EP2547205B1 (en) 2024-03-20
AU2011227023B2 (en) 2015-05-28
US20170319537A1 (en) 2017-11-09
ES2987670T3 (es) 2024-11-15
BR112012023660B1 (pt) 2021-05-18
BR112012023660A2 (pt) 2015-09-15
LT2547205T (lt) 2024-06-10
HRP20240658T1 (hr) 2024-08-16
FI2547205T3 (fi) 2024-05-27

Similar Documents

Publication Publication Date Title
SI2547205T1 (sl) Novi postopki za ciljanje rakastih matičnih celic
IL220756A0 (en) Herbicide-tolerant plants
IL225635A0 (en) Supplement for cell culture
PT2785834T (pt) Composição de células estaminais melhorada
PT2547205T (pt) Novos métodos para atingir células estaminais cancerígenas
EP2601290A4 (en) SOMATIC STEM CELLS
EP2772268B8 (en) Cancer stem cell-specific molecule
GB201016139D0 (en) Cancer phosholipidome
IL255309B (en) Reprogramming of cancer cells
LT2547766T (lt) Herbicidams atsparūs augalai
EP2760996A4 (en) SOMATIC STEM CELLS
GB201012590D0 (en) Methods for diagnosing cancer
WO2011116344A9 (en) Targeting cancer stem cells
EP2533789A4 (en) METHOD FOR IMPROVING THE FUNCTIONALITY OF SPERM
HUE039389T2 (hu) Az anti-EMP2 terápia csökkenti a rák õssejteket
PT3536334T (pt) Vacinas contra o cancro dirigidas a células estaminais cancerígenas
PL2568796T3 (pl) Półzawieszany pług obracalny
WO2012106368A9 (en) Methods for inhibiting prostate cancer
SG196714A1 (en) Cancer stem cell inhibition
GB201021372D0 (en) CD24 cancer stem cell
ZA201205860B (en) Herbicide-tolerant plants
AU2011900981A0 (en) Inhibition of cancer stem cells
GB201012495D0 (en) Targeted differntiation of stem cells
PL2593113T3 (pl) Terapia komórkowa
GB201020580D0 (en) Cells